Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Goodwill
The premium paid for acquisitions above the fair value of the identifiable net assets acquired.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Goodwill · Q1 FY2026 · quarter ended Mar 2026
Goodwill remains negative
Q1 FY2026 goodwill was $0, compared with $0 a year earlier.
Context
- Goodwill amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Goodwill increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Goodwill history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Goodwill | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Goodwill vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's Mar 2026 goodwill of $0 is the highest of the 3 companies compared; the peer median is $0.
- Goodwill amounts to 0.0% of total assets for IRWD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IRWD) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 620.13M | 656.2M | 92.15M | 88.56M | 215.46M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 114.04M | 115.46M | 129.12M | 81.89M | 46.75M |
| Inventory | 0 | 1.25M | 0 | 0 | 0 |
| Other Current Assets | 2.37M | 0 | 0 | 11.92M | 11.98M |
| Total Current Assets | 745.23M | 780.63M | 233.29M | 182.37M | 274.18M |
| Property, Plant & Equipment (Net) | 22.93M | 20.31M | 18.17M | 15.52M | 12.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 3.68M | 2.86M | 2.04M |
| Long-term Investments | 0 | 15.07M | 0 | 0 | 0 |
| Tax Assets | 333.29M | 283.66M | 212.32M | 144.23M | 103.43M |
| Other Non-current Assets | 25.48M | 847K | 3.61M | 5.92M | 4.5M |
| Total Non-current Assets | 381.7M | 319.89M | 237.79M | 168.54M | 122.72M |
| Total Assets | 1.13B | 1.1B | 471.07M | 350.91M | 396.9M |
| Account Payables | 935K | 483K | 7.83M | 2.13M | 2.9M |
| Short-term Debt | 116.86M | 0 | 199.56M | 0 | 199.68M |
| Tax Payables | 0 | 656K | 1.24M | 521K | 0 |
| Deferred Revenue | 0 | 0 | 2.62M | 2.03M | 1.11M |
| Other Current Liabilities | 7.49M | 15.88M | 26.13M | 4.98M | 21M |
| Total Current Liabilities | 161.7M | 25.53M | 276.1M | 38.85M | 242.22M |
| Long-term Debt | 337.33M | 396.25M | 498.31M | 583.99M | 385M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 3.5M | 9.77M | 28.42M | 17.11M | 21.65M |
| Total Non-current Liabilities | 359.32M | 422.62M | 541.27M | 613.4M | 416.52M |
| Total Liabilities | 521.02M | 448.14M | 817.37M | 652.24M | 658.74M |
| Common Stock | 162K | 154K | 156K | 160K | 163K |
| Retained Earnings | (937.61M) | (696.38M) | (1.7B) | (1.7B) | (1.67B) |
| Accumulated OCI | (0) | 0 | (3.03M) | 923K | (1.06M) |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 605.91M | 652.38M | (346.3M) | (301.34M) | (261.83M) |
| Total Debt | 475.8M | 415.92M | 715.54M | 599.48M | 597.8M |
| Net Debt | (144.33M) | (240.29M) | 623.38M | 510.92M | 382.35M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.